Entries by Max

UPDATE: EIK1003 Plus Abiraterone Shows Early Activity in HRR-Mutated Prostate Cancer

/in , , , /by

New results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]

UPDATE: CONVERGE-01 Trial Reports 83% PSA50 Response in Patients Without Prior Lu-PSMA

/in , , /by

New results from the phase 2 CONVERGE-01 trial,  show preliminary antitumor activity of CONV01-α, an experimental PSMA-targeted alpha therapy, in patients with metastatic androgen pathway inhibitor-resistant prostate cancer (mCRPC) who had not previously received Lu-PSMA radioligand therapy. CONV01-α, also known as ²²⁵Ac-rosopatamab tetraxetan, combines the alpha-emitting isotope actinium-225 with a monoclonal antibody targeting PSMA. Unlike […]

UPDATE: Gedatolisib Plus Darolutamide Shows Activity in mCRPC

/in , , , /by

Updated results from the phase 1/2 CELC-G-201 trial (we talked about it in this previous article) provide new evidence of antitumor activity for gedatolisib combined with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors (ARPIs). Gedatolisib inhibits the PI3K–AKT–mTOR signaling pathway, which can contribute to resistance to […]

Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer

/in , , /by

Updated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]

Phase 2 ExBAT Trial: AR Amplification Linked to Poorer Outcomes With Alternating Testosterone and Darolutamide

/in , , /by

New biomarker findings from the phase 2 ExBAT trial, suggest that androgen receptor (AR) amplification may be associated with poorer outcomes in patients receiving alternating bipolar androgen therapy (BAT) and darolutamide for metastatic castration-resistant prostate cancer (mCRPC). ExBAT/LACOG 0620 investigated an experimental strategy combining periods of supraphysiological testosterone exposure with subsequent androgen receptor inhibition. Patients […]

Phase 1 Trial: Astatine-211 PSMA-5 Shows Strong Early Responses in First-in-Human Prostate Cancer Trial

/in , , /by

Encouraging results suggest that 211At-PSMA-5, an experimental alpha-emitting radioligand targeting PSMA, may offer a promising new treatment approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human phase 1 study involving 15 patients whose disease had progressed following androgen receptor pathway inhibitors and taxane-based chemotherapy. Unlike established PSMA-targeted radioligand therapy […]

Phase 2 Trial: DLL3 PET Reveals Tumor Heterogeneity in Neuroendocrine Prostate Cancer

/in , , /by

New findings suggest that an experimental PET imaging technique targeting DLL3 could help identify neuroendocrine prostate cancer (NEPC) lesions and reveal important differences between metastases within the same patient. Neuroendocrine prostate cancer is an aggressive form of the disease that can emerge following prolonged treatment with androgen receptor-targeted therapies. These tumors frequently show reduced PSMA […]

Phase 1 Trial for SHR-4394: PSMA-Targeted ADC Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results provide encouraging preliminary evidence of antitumor activity for SHR-4394, an investigational antibody-drug conjugate (ADC) targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human 1hase 1 study evaluating SHR-4394 as a standalone treatment. The drug is designed to recognize PSMA, a protein frequently expressed on prostate cancer cells, and […]

UPDATE: TALAPRO-3, New Analysis Explores Talazoparib Benefit Across HRR Gene Mutations

/in , /by

New exploratory biomarker findings from the phase 3 TALAPRO-3 trial, provide further insight into how patients with different DNA repair gene alterations respond to the combination of talazoparib and enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC). TALAPRO-3 previously demonstrated a significant improvement in radiographic progression-free survival (rPFS) with the addition of the PARP inhibitor talazoparib […]

Younger Men Face Higher Mortality Risk in Advanced Prostate Cancer: An Analysis of IRONMAN Registry Data

/in /by

Younger age is generally associated with better health and longer life expectancy. However, new findings from the international IRONMAN registry suggest a different pattern in advanced prostate cancer: men diagnosed at age 55 or younger may have worse survival outcomes than those diagnosed at middle or older ages. The analysis included 4,332 patients from 15 […]